Get the Stockscreener App
18.62
1.53%
-0.29
Summit Therapeutics Inc stock is traded at $18.62, with a volume of 1.35M.
It is down -1.53% in the last 24 hours and down -13.11% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$18.91
Open:
$18.74
24h Volume:
1.35M
Relative Volume:
0.35
Market Cap:
$13.83B
Revenue:
$220.00K
Net Income/Loss:
$-746.08M
P/E Ratio:
-18.48
EPS:
-1.0074
Net Cash Flow:
$-211.81M
1W Performance:
-4.32%
1M Performance:
-13.11%
6M Performance:
-33.26%
1Y Performance:
-1.95%
1-Day Range:
$18.45
$19.18
1-Week Range:
$18.38
$19.76
52-Week Range:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
18.62 | 14.08B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.76 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.33 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.30 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.16 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
What MACD and RSI say about Summit Therapeutics Inc.2025 Short Interest & Accurate Technical Buy Alerts - newser.com
What institutional flow reveals about Summit Therapeutics Inc.Market Growth Report & Safe Capital Growth Tips - newser.com
Is Summit Therapeutics Inc. stock reversal real or fakeMarket Trend Report & Weekly Market Pulse Alerts - newser.com
1 Monster Stock in the Making to Buy and Hold - AOL.com
Is Summit Therapeutics Inc. showing signs of accumulationProduct Launch & High Return Stock Watch Alerts - newser.com
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
News impact scoring models applied to Summit Therapeutics Inc.Portfolio Value Report & Weekly Hot Stock Watchlists - newser.com
Insiders Are Snapping Up These 2 Stocks — and Analysts Like What They See - Yahoo Finance
Should you hold or exit Summit Therapeutics Inc. now2025 Volume Leaders & High Conviction Investment Ideas - newser.com
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 - Business Wire
Can Summit Therapeutics Inc. hit a new high this monthDollar Strength & Short-Term Trading Alerts - newser.com
Applying sector rotation models to Summit Therapeutics Inc.2025 Breakouts & Breakdowns & Weekly Chart Analysis and Trade Guides - newser.com
Jefferies Cuts Summit Therapeutics (SMMT) Price Target, Keeps Buy Rating - Insider Monkey
Summit Therapeutics (SMMT) Releases Financial Results and Updates on Operational Progress for Q3 2025 - Insider Monkey
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
13 Stocks to Buy with Exponential Growth Heading into 2026 - Insider Monkey
10 Stocks Under $20 to Buy According to Analysts - Insider Monkey
Summit Therapeutics (SMMT) Aims for FDA Nod for Ivonescimab in N - GuruFocus
Summit Therapeutics (SMMT) files for 26.68M share offering by selling stockholders - StreetInsider
Why Wall Street Is Backing These 3 Comeback Stocks - Investing.com
Patterns Watch: Is Summit Therapeutics Inc. stock a safe haven asset2025 Volume Leaders & Weekly High Return Stock Forecasts - fcp.pa.gov.br
Co-CEO & Executive Chairman of Summit Therapeutics Picks Up 2.5% More Stock - simplywall.st
Co-CEO & Executive Chairman of Summit Therapeutics Robert Duggan Buys 2.5% More Shares - Yahoo Finance
Insider Spends US$262m Buying More Shares In Summit Therapeutics - 富途牛牛
Can Summit Therapeutics Inc. stock outperform in 2025 bull marketEarnings Overview Summary & Real-Time Volume Analysis Alerts - Fundação Cultural do Pará
Analyzing Summit Therapeutics Inc. with risk reward ratio charts2025 Price Targets & High Return Stock Watch Alerts - newser.com
Allianz Asset Management GmbH Decreases Stock Holdings in Summit Therapeutics PLC $SMMT - MarketBeat
What margin trends mean for Summit Therapeutics Inc. stock2025 Top Decliners & Fast Exit/Entry Strategy Plans - fcp.pa.gov.br
Summit Therapeutics proves InvestingPro’s Fair Value accuracy with 40% return By Investing.com - Investing.com South Africa
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):